Validating rnai targets
After adding a plate carousel to the machine, it can screen about 30 plates a day, in 96- or 384-well format, he says.Multiplexed assay designed to identify and distinguish targets that have effects on apoptosis or cell cycle.Image-Based Assay for Biological Endpoints The key to high-content screening is properly integrating the instrument's different technologies, says Sarah Tencza, product manager for bioapplications at Cellomics Inc., Pittsburgh.
They can now perform assays for gene transcription, protein translocation, protein phosphorylation and cell cycle changes."The goal of the instrument is to allow the quantitation of cell biology experiments on a scale that gives you statistical relevance and reasonable throughput," says Tencza."The integration in the data management becomes extremely important when you're talking about not just scan time or image acquisition time, but the time that's required from an assay concept to getting the results." The instruments provide more than mere image analysis, says Mark Collins, senior product manager for informatics at Cellomics.Researchers can now combine the two tools to screen potential targets systematically, exploiting the rich information set provided by HCS to make what may turn out to be better decisions about the molecules they will send to chemists.This new wealth of information, however, creates information management challenges for both pharmaceutical researchers and instrument vendors.